Adlai Nortye Group (ANL) vs Geron (GERN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Adlai Nortye Group (ANL) has outperformed Geron (GERN) over the past year, gaining 572.6% versus a loss of 2.5%. Geron is the larger company by market cap ($751.7 million vs $710.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANL | GERN |
|---|---|---|
| Share price | $11.03 | $1.17 |
| Market cap | $710.31M | $751.69M |
| 1-day change | -8.77% | -4.88% |
| YTD return | +676.76% | -11.36% |
| 1-year return | +572.56% | -2.50% |
| 5-year return | — | -19.31% |
| Forward P/E | — | 29.25 |
| EPS (TTM) | $-0.66 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-51.87M | $-83.50M |
| 52-week high | $17.25 | $2.01 |
| 52-week low | $0.879 | $1.04 |
| Distance from 52-week high | -36.06% | -41.79% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +167.45% | +263.25% |
| Average volume | 212.90K | 9.84M |
| Shares outstanding | 58.73M | 642.47M |
| Employees | 109 | 258 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANL has outperformed GERN by 575.1 percentage points over the past year.
About Adlai Nortye Group
ANL stock →Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 109 employees
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
ANL vs GERN FAQ
Which is bigger, Adlai Nortye Group or Geron?
Geron (GERN) is larger, with a market capitalization of $751.69M compared with $710.31M for Adlai Nortye Group (ANL).
Which stock has performed better over the past year, ANL or GERN?
ANL returned +572.56% over the past 12 months, compared with -2.50% for GERN (price return, excluding dividends). Past performance does not predict future results.
Are Adlai Nortye Group and Geron in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.